−1.87USD
−132.53 MUSD
377.71 MUSD
67.88 M
About Beam Therapeutics Inc.
Sector
Industry
CEO
John Evans
Website
Headquarters
Cambridge
Employees (FY)
436
Founded
2017
ISIN
US07373V1052
FIGI
BBG00KXC8646
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
Beam $BEAM Long In the case of Beam Therapeutics ( NASDAQ:BEAM ), the weekly chart displays a promising pattern characterized by a higher low, indicating a potential bottoming process in the stock's price movement. This higher low suggests a reversal of the previous downtrend and potentially signals a shift towards
March Gainers (BEAM, account up 1%)2nd gainer in March is BEAM . Holding period is 0 days (3/13/23-3/13/23). Account is up 1%.
This month till today, my account is up 2%
My trading method is mostly short term and is independent of market swings.
Will keep updating on my trades.
1/4/2022 NASDAQ (BEAM)Short (Entry Price) below the black line and exit (Stop Loss) above the red line. Can take profit at the suggested Target Price.
Entry Price: $59.14
Target Price: $56.35
Stop Loss: $63.79
28/3/2022 NASDAQ (BEAM)Short (Entry Price) below the black line and exit (Stop Loss) above the red line. Can take profit at the suggested Target Price.
Entry Price: $57.83
Target Price: $55.93
Stop Loss: $61.00
24/3/2022 NASDAQ (BEAM)Short (Entry Price) below the black line and exit (Stop Loss) above the red line. Can take profit at the suggested Target Price.
Entry Price: $59.01
Target Price: $57.11
Stop Loss: $62.22
22/3/2022 NASDAQ (BEAM)Short (Entry Price) within the sell zone area and exit (Stop Loss) above the red line. Can take profit at the suggested Target Price.
Entry Price: $61.47 / $60.27
Target Price: $58.83 / $56.91
Stop Loss: $65.87
3/3/2022 NASDAQ (BEAM)Buy (Entry Price) above the black line and exit (Stop Loss) below the red line. Can take profit at the suggested Target Price.
Entry Price: $74.49
Target Price: $77.76
Stop Loss: $69.04
Beam me up, Scotty! BEAMWe are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistic
$BEAM at an Interesting Spot$BEAM recovered on earning and after shaking out few traders Friday.
Back on my list. Interesting spot here.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of BEAM is 24.31 USD — it hasn't changed in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Beam Therapeutics Inc. stocks are traded under the ticker BEAM.
Beam Therapeutics Inc. is going to release the next earnings report on May 7, 2024. Keep track of upcoming events with our Earnings Calendar.
BEAM stock is 3.04% volatile and has beta coefficient of 3.15. Check out the list of the most volatile stocks — is Beam Therapeutics Inc. there?
One year price forecast for Beam Therapeutics Inc. has a max estimate of 78.00 USD and a min estimate of 27.00 USD.
BEAM earnings for the last quarter are −1.22 USD whereas the estimation was −1.33 USD which accounts for 8.18% surprise. Estimated earnings for the next quarter are −0.69 USD. See more details about Beam Therapeutics Inc. earnings.
Beam Therapeutics Inc. revenue for the last quarter amounts to 17.19 M USD despite the estimated figure of 17.09 M USD. In the next quarter revenue is expected to reach 18.67 M USD.
Yes, you can track Beam Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
BEAM stock has fallen by 11.57% compared to the previous week, the month change is a 28.18% fall, over the last year Beam Therapeutics Inc. has showed a 20.92% decrease.
BEAM net income for the last quarter is 142.80 M USD, while the quarter before that showed −96.09 M USD of net income which accounts for 248.61% change. Track more Beam Therapeutics Inc. financial stats to get the full picture.
Today Beam Therapeutics Inc. has the market capitalization of 1.99 B, it has decreased by 5.70% over the last week.
No, BEAM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, BEAM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Beam Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 436.00 employees. See our rating of the largest employees — is Beam Therapeutics Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Beam Therapeutics Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Beam Therapeutics Inc. stock shows the strong sell signal. See more of Beam Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Beam Therapeutics Inc. future price: according to them, BEAM price has a max estimate of 78.00 USD and a min estimate of 27.00 USD. Read a more detailed Beam Therapeutics Inc. forecast: see what analysts think of Beam Therapeutics Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Beam Therapeutics Inc. EBITDA is −149.36 M USD, and current EBITDA margin is −41.43%. See more stats in Beam Therapeutics Inc. financial statements.